Alprazolam
1.
Alpragen contains the active substance alprazolam, which belongs to a group of medicines called benzodiazepines.
Alpragen is indicated for the treatment of anxiety symptoms in adults, only in situations where the symptoms are severe, prevent normal functioning, or are very troublesome for the patient. This medicine is intended for short-term use only.
Before starting to take Alpragen, the patient should discuss it with their doctor or pharmacist
During treatment with Alpragen, the patient may experience anterograde amnesia. To minimize the risk, the patient should have uninterrupted sleep for 7-8 hours during treatment.
Alprazolam use has been associated with unusual reactions, such as: anxiety, especially motor, agitation, irritability, aggression, delusions, outbursts of anger, nightmares, hallucinations (seeing or hearing things that do not exist), psychosis (loss of contact with reality), and strange behavior. If such symptoms occur, the patient should consult their doctor, as it may be necessary to stop taking the medicine.
Alpragen is not recommended for children and adolescents under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those available without a prescription. It is especially important to inform the doctor about the use of medicines such as:
Taking Alpragen with opioids (strong painkillers, medicines used in substitution therapy for opioid addiction, some antitussive medicines) increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and can be life-threatening.
Deaths have been reported. For this reason, concurrent use should only be considered when other treatment methods are not possible.
However, if the doctor prescribes Alpragen with opioids, the dosage and duration of such treatment should be limited by the attending physician.
The patient should inform their doctor about all opioid medicines they are taking and strictly follow the dosage prescribed by their doctor. It may be helpful to inform friends or family about the above symptoms. If such symptoms occur, the patient should contact their doctor.
In the event of planned surgery under general anesthesia, the patient should inform their doctor about taking alprazolam.
The patient should not drink alcohol while taking Alpragen; alcohol enhances the effect of Alpragen.
The patient should not drink too much grapefruit juice while taking this medicine, as it may increase the amount of alprazolam in the blood.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine. The patient should not take Alpragen if they are pregnant without discussing the possible risks and benefits of taking this medicine with their doctor.
If alprazolam is taken regularly in the last trimester of pregnancy, the baby may experience dependence on alprazolam and withdrawal symptoms after birth.
If the doctor decides to use alprazolam in late pregnancy or during childbirth, the baby may experience symptoms such as low body temperature, limpness, breathing difficulties, and feeding problems, tremors, increased excitability, and agitation.
The patient should not take Alpragen while breastfeeding, as the medicine may pass into breast milk.
The patient should not drive or operate machinery after taking alprazolam, as they may experience symptoms such as: loss of concentration, loss of muscle control, memory loss, dizziness, drowsiness, or confusion.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking Alpragen.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
The medicine contains 0.1 mg of sodium benzoate per tablet.
Sodium benzoate may increase the risk of jaundice (yellowing of the skin and whites of the eyes) in newborns (up to 4 weeks of age), but this medicine is not recommended for use in patients under 18 years of age.
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist.
The recommended dose is 0.25 mg to 0.5 mg three times a day.
If necessary, the doctor may decide to increase the dose to a maximum of 4 mg per day. In case of doubts, the patient should consult their doctor or pharmacist again. The patient should be cautious when increasing the dose. The patient should first increase the evening dose, and then the daytime dose.
In patients who have not taken this type of medicine before and in patients with a history of alcoholism, a lower dose should be used.
The recommended dose for elderly patients is 0.25 mg two to three times a day. In elderly patients in good physical condition, the doctor may increase the dose by 0.5 mg every third day, up to a maximum dose of 1.5 mg per day. In frail elderly patients, the dose should not exceed 0.75 mg per day.
Alpragen should be taken orally. The score line on the tablet is only to facilitate breaking the tablet for easier swallowing.
In cases of liver or kidney impairment, the doctor may recommend a lower dose than usual. The maximum recommended dose for patients with liver or kidney impairment is 0.75 mg to 1.5 mg per day.
Alpragen should not be taken for longer than prescribed by the doctor. The total treatment duration should not exceed 2-4 weeks. Taking alprazolam for too long and in too high a dose may lead to the development of psychological and physical dependence. The patient should not stop treatment prematurely.
In case of taking a higher dose than recommended, the patient should immediately contact their doctor or go to the emergency department of the nearest hospital. The patient should take the packaging of the medicine and any remaining tablets with them. Symptoms of overdose include: drowsiness, confusion, lack of coordination or unsteady movements, breathing difficulties, low blood pressure, fatigue, loss of consciousness, and in rare cases, death.
The patient should not take a double dose to make up for a missed dose; they should only take the next dose at the right time.
The patient should not stop taking Alpragen on their own. Before stopping treatment, the dose of the medicine should be gradually reduced. The doctor will inform the patient how to do this. If the patient stops taking Alpragen too early, they may experience symptoms such as: anxiety, restlessness, especially motor, seizures, headaches, muscle pain, tension, confusion, irritability, involuntary movements, and difficulty sleeping.
In severe cases, symptoms may also include loss of consciousness, loss of contact with reality, increased sensitivity to light, sound, and touch, feeling of numbness or tingling in the limbs, seeing or hearing things that do not exist, seizures, abdominal cramps and muscle spasms, vomiting, sweating, and shivering.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Alpragen can cause side effects, although not everybody gets them.
In people with a history of violence, borderline personality disorders, alcohol abuse, and those taking medicines that affect the central nervous system, hostile or aggressive behavior has been observed. If the patient has post-traumatic stress disorder, stopping treatment with Alpragen may cause irritability, hostility, and unpleasant thoughts and reflections.
Common side effects are usually observed at the beginning of treatment with Alpragen. These symptoms usually disappear during continued treatment.
The patient should immediately inform their doctorif they experience any of the following side effects, as they may be serious:
Uncommon(may affect up to 1 in 100 people)
Side effects with unknown frequency(frequency cannot be estimated from the available data)
The patient should stop taking the medicine. The doctor will inform the patient how to do this.
Other side effects
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Side effects with unknown frequency(frequency cannot be estimated from the available data)
If the patient experiences any side effects, including those not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products,
Jerozolimskie Avenue 181C, phone: 22 49 21 301, fax: 22 49 21 309,
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Store in a temperature below 25°C. Store in the original packaging to protect from light and moisture.
“EXP”.The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
0.25 mg tablets: white, oval tablets with the inscription “AL” and a score line “0.25” on one side and “G” on the other side.
0.5 mg tablets: pink, oval tablets with the inscription “AL” and a score line “0.5” on one side and “G” on the other side.
1 mg tablets: light blue, oval tablets with the inscription “AL” and a score line “1.0” on one side and “G” on the other side.
Alpragen is available in packs containing 30 or 60 tablets in blisters.
Not all pack sizes may be marketed.
Marketing authorization holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
DUBLIN
Ireland
Manufacturer
McDermott Laboratories Ltd., trading as Gerard Laboratories Ltd.
35/36 Baldoyle Industrial Estate
Grange Road, Dublin 13
Irlandia
Mylan Hungary Kft.
Mylan utca 1.
Komárom, 2900
Hungary
To obtain more detailed information, the patient should contact the representative of the marketing authorization holder:
phone: +48 22 54 66 400
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.